Back to Clinical Trials Overview

Your search for "Liver Disorders" returned 27 results:


A Phase 2, randomized, multicenter, placebo-controlled, double-blind, parallel-group study to evaluate the efficacy, safety and population PKs of once-daily oral E5501 tablets used up to 7 days in subjects with chronic liver diseases and thrombocytopenia prior to elective surgical or diagnostic procedures
Principal Investigator(s): Chang, Charissa

Genomics of Primary Biliary Cirrhosis
Principal Investigator(s): Joseph Odin

Detection of Liver Fibrosis Using Advanced MRI Methods
Principal Investigator(s): Bachir Taouli

Treatment of Hepatitis C in Primary Care Setting
Principal Investigator(s): McGinn, Thomas

Biliary Atresia Study in Infants and Children (BASIC)
Principal Investigator(s): Suchy, Frederick J.

CBT to Prevent Depression in Mono and Co-Infected HIV/HCV
Principal Investigator(s): McGinn, Thomas

Tenofovir Disoproxil Fumarate v. Emtricitabine for Hep B
Principal Investigator(s): Liu, Lawrence

Cholestatic Liver Disease Consortium- Longitudinal Studies of Genetic Causes of Intrahepatic Cholestasis(LOGIC)
Principal Investigator(s): Suchy, Frederick J.

A Rollover Protocol to Provide Open-Label Emtricitabine/Tenofovir Disoproxil Fumarate Combination Product to Subjects Completing the GS-US-203-0107 Study. Protocol GS-US-203-0109
Principal Investigator(s): Schiano, Thomas

Comparative Study of Hepatitis B Pts:The BE-LOW Study
Principal Investigator(s): Dieterich, Douglas

Hepatitis C Primary Care Cohort
Principal Investigator(s): McGinn, Thomas

Prospective Database of Infants with Cholestasis (PROBE)
Principal Investigator(s): Suchy, Frederick J.

2 Dose Regimens of Telaprevir in Comb. w/Pegasys&Copegus
Principal Investigator(s): Dieterich, Douglas

Evaluation of Tenofovir DF vs. Adefovir Dipivoxil
Principal Investigator(s): Odin, Joseph A

Postoperative Anaglesia Liver Resection Opioids
Principal Investigator(s): Wax, David

A Randomized Study of Stopping Treatment at 24 Weeks or Continuing Treatment to 48 Weeks in Treatment -Naive Subjects with Genotype 1 Chronic Hepatitis C who Achieve an Extended Rapid Viral Response (eRVR) while Receiving Telaprevir, Peginterferon Alfa2a (Pegasys) and Ribavirin (Copegus) [VX08-950-111]
Principal Investigator(s): Dieterich, Douglas

Characterization of Acute HCV Infection
Principal Investigator(s): Fierer, Daniel S

Entecavir (ETV) in Pediatric Subjects w/HBV & HBeAG-+
Principal Investigator(s): Kerkar, Nanda

Tenofovir DF vs. Adefovir Dipivoxil Chronic Hepatitis
Principal Investigator(s): Odin, Joseph A

Longitudinal Study of Mitochondrial Hepatopathies (MITOHEP)
Principal Investigator(s): Suchy, Frederick J.

HCC BRIDGE study: Bridge to better outcomes in HCC
Principal Investigator(s): Schwartz, Myron MD

A Phase 2b, Dose-Ranging, Randomized, Double-Blind, Placebo-Controlled Trial Evaluating the Safety and Efficacy of GS-6624, a Monoclonal Antibody Against Lysyl Oxidase Like 2 (LOXL2) in Subjects with Primary Sclerosing Cholangitis (PSC)
Principal Investigator(s): Joseph Odin

Corticosteroid Therapy in Infants w/ Bilary Atresia (START Trial)
Principal Investigator(s): Suchy, Frederick J.

Telaprevir (VX-950) Pegasys & Copegus in Hepatitis C
Principal Investigator(s): Dieterich, Douglas

Multiple Rising Oral Doses of BI 201335 NA for Hepatitis
Principal Investigator(s): Dieterich, Douglas

A Phase 2b Randomized, Double-Blind, Placebo-Controlled Trial Comparing 24, or 48 Weeks of GS-9190, in Combination with Peginterferon Alfa 2a and Ribavirin, to 48 weeks of Peginterferon Alfa 2a and Ribavirin for the Treatment of Genotype-1 Chronic Hepatitis C Virus (HCV) Infection
Principal Investigator(s): Odin, Joseph A

Antiviral Effect, Safety, & Pharmacokinetics of once Daily BI 201335 NA in Hepatitis C Virus Genotype 1 Infected Treatment-Naive Patients for 24 weeks as Combination Therapy with Pegylated Interferon-a 2a and Ribavirin
Principal Investigator(s): Dieterich, Douglas